Natalie K. Rynkiewicz

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.

Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study.

Journal: Immunotherapy
Published: September 01, 2025

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.

Journal: The Journal of allergy and clinical immunology
Published: July 26, 2024

The role of OX40 ligand/OX40 axis signalling in atopic dermatitis.

The role of OX40 ligand/OX40 axis signalling in atopic dermatitis.

Journal: The British journal of dermatology
Published: March 21, 2024

A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice.

A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice.

Journal: Blood advances
Published: October 25, 2023

Gβγ is a direct regulator of endogenous p101/p110γ and p84/p110γ PI3Kγ complexes in mouse neutrophils.

Gβγ is a direct regulator of endogenous p101/p110γ and p84/p110γ PI3Kγ complexes in mouse neutrophils.

Journal: Science signaling
Published: November 04, 2020

INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.

INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.

Journal: Nature communications
Published: October 06, 2020

Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML.

Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML.

Journal: Blood
Published: September 27, 2014

INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival.

INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival.

Journal: The Prostate
Published: April 08, 2014

Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells.

Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells.

Journal: Bioscience reports
Published: December 10, 2013
Showing 1-9 of 9

Last Updated: 09/26/2026